ClinicalTrialStartPulse / report
Keymed Biosciences Co.Ltd: Phase 3 study in Multiple Myeloma (MM) (320 participants)
Keymed Biosciences Co.Ltd: Phase 3 study in Multiple Myeloma (MM) (320 participants). Its enrollment of 320 is above the median of 80 (84th percentile). Dated 2 days ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-03, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 320 · 84th percentile of 8,570 ClinicalTrialStartPulse records · 4.0x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Keymed Biosciences Co.Ltd |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma |
| NCT ID | NCT07910903 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Multiple Myeloma (MM) |
| Intervention types | drug |
| Target enrollment | 320 |
| Site countries | China |
| Posted | 2026-11-02 |
| Planned start | 2026-12 |
| Event | Newly registered study |
| Event date | 2026-11-02 |
| enrollment percentile | 84th of 8,570 (median 80, 4.0x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Keymed Biosciences Co.Ltd
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Keymed Biosciences Co.Ltd + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-02
- Data refreshed: 2026-11-03
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Tue, 03 Nov 2026 05:11:05 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Keymed Biosciences Co.Ltd and 6,377 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,377
- Keymed Biosciences Co.Ltd's enrollment: 84th percentile of 8,570 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,275,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 320 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Keymed Biosciences Co.Ltd?
Keymed Biosciences Co.Ltd registered a Phase 3 study (NCT07910903) in Multiple Myeloma (MM) targeting 320 participants, posted 2026-11-02.
How does Keymed Biosciences Co.Ltd compare to other ClinicalTrialStartPulse records?
Its enrollment of 320 sits in the upper half (84th percentile) of 8,570 records; the median is 80. It is fresh: dated 2 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Keymed Biosciences Co.Ltd vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Keymed Biosciences Co.Ltd | NONUS | 320 | 84th | 2026-11-02 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | NONUS | 206 | 77th | 2026-11-02 |
| Merck Sharp & Dohme LLC | NONUS | 150 | 71st | 2026-11-02 |
| Merck Sharp & Dohme LLC | NONUS | 564 | 90th | 2026-11-02 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Keymed Biosciences Co.Ltd and peer phase 3 records
Get new ClinicalTrialStartPulse records like Keymed Biosciences Co.Ltd by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.